uniQure N.V. (QURE)
NASDAQ: QURE · Real-Time Price · USD
16.65
-0.49 (-2.86%)
Apr 8, 2026, 12:46 PM EDT - Market open
uniQure Revenue
In the year 2025, uniQure had annual revenue of $16.10M, down -40.64%. uniQure had revenue of $5.57M in the quarter ending December 31, 2025, with 6.65% growth.
Revenue (ttm)
$16.10M
Revenue Growth
-40.64%
P/S Ratio
66.58
Revenue / Employee
$72,842
Employees
221
Market Cap
1.04B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 16.10M | -11.02M | -40.64% |
| Dec 31, 2024 | 27.12M | 11.28M | 71.17% |
| Dec 31, 2023 | 15.84M | -90.64M | -85.12% |
| Dec 31, 2022 | 106.48M | -417.52M | -79.68% |
| Dec 31, 2021 | 524.00M | 486.49M | 1,296.82% |
| Dec 31, 2020 | 37.51M | 30.23M | 415.23% |
| Dec 31, 2019 | 7.28M | -4.00M | -35.48% |
| Dec 31, 2018 | 11.28M | -1.82M | -13.91% |
| Dec 31, 2017 | 13.11M | -11.99M | -47.78% |
| Dec 31, 2016 | 25.10M | 14.52M | 137.27% |
| Dec 31, 2015 | 10.58M | 4.44M | 72.25% |
| Dec 31, 2014 | 6.14M | 2.09M | 51.74% |
| Dec 31, 2013 | 4.05M | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | - | - | - |
| Dec 31, 2006 | 68.42K | -174.98K | -71.89% |
| Dec 31, 2005 | 243.40K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Pharming Group | 376.13M |
| Xeris Biopharma Holdings | 291.85M |
| Geron | 183.88M |
| AbCellera Biologics | 75.13M |
| KalVista Pharmaceuticals | 73.62M |
| Septerna | 45.95M |
| EyePoint | 31.37M |
| Inventiva | 9.31M |
QURE News
- 5 days ago - UNIQURE DEADLINE APPROACHING: Bragar Eagel & Squire, P.C. Encourages uniQure N.V. - GlobeNewsWire
- 8 days ago - QURE SHAREHOLDER NOTICE: Hagens Berman Updates uniQure (QURE) Investigation Following Public FDA Rebukes and Allegations of "Distorted" Data - PRNewsWire
- 4 weeks ago - This biotech's stock is soaring after a ‘polarizing' FDA official is stepping down - Market Watch
- 4 weeks ago - Federal health officials attacked an Amsterdam-based biotech company seeking approval of a Huntington's disease treatment and accused it of lying - WSJ
- 4 weeks ago - FDA official calls UniQure's gene therapy a 'failed' treatment for Huntington's disease - CNBC
- 4 weeks ago - Sr. FDA official calls Uniqure's Huntington's disease treatment a failure - Reuters
- 4 weeks ago - FDA Defends Call For Placebo Study In uniQure Huntington's Gene Therapy Trial - Benzinga
- 4 weeks ago - FDA official says UniQure fell short on Huntington's trial, defends new study request - Reuters